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constitute a reward for manufacturers, however, various benefits have been re-
ported such as reimbursement for drugs which received an initial negative recom-
mendation (e.g. bortezomib and trabectedin, UK) and competitive advantage in the
form of better formulary position (sitagliptin & sitagliptin  metformin, USA); not
to mention the possibility of granting discounts while leaving list prices un-
touched. Considerable administrative burden is placed on health care staff due to
the diversity of existing schemes, the complexities linked with retrospective reim-
bursement, and lack of management capacity at current staffing levels.
CONCLUSIONS: Although evidence on the impact of MEs is patchy, the systematic
literature review showed that there are already lessons to be learnt. Preliminary
findings seem to suggest that MEs have indeed the potential of meeting payer,
patient, and manufacturer expectations, yet important threats such as implemen-
tation difficulties, administrative burden and lack of management capacity need to
be addressed.
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OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become common in
health technology submissions, and have been instrumental in enhancing the
availability of otherwise non cost-effective treatments. Despite notable efforts to-
wards recognising and reducing the administrative impact of PAS on frontline
staff, evidence suggests that they still result in a significant burden. The study
presented here attempted to assess the burden of PAS administration, and how
this could change if and when the planned changes to the UK healthcare system
are enacted. METHODS: A literature search was conducted and freedom-of-infor-
mation requests were sent to the Patient Access Scheme Liaison Unit (PASLU) for
data on PAS administration. A questionnaire developed from our previous pilot
study on the administrative burden of PAS was distributed to hospital pharmacists
across the UK, and a call for participants was hosted on the Royal Pharmaceutical
Society website.RESULTS:Value Based Pricing (VBP) is expected to be introduced in
the UK once the current Pharmaceutical Price Regulation Scheme comes to an end.
PAS approved before this point will continue to be used, although additional PAS
may not be introduced under VBP. It is unclear from the available literature how
this will affect the role of PASLU and the administration of the remaining PAS. The
return-rate for our questionnaire was low; however, responders voiced similar
concerns to those recorded in our pilot study, namely the poor recognition of the
burden of PAS and the resources required to manage them. Responders were also
unclear about how administration of PAS would change with the move to VBP.
CONCLUSIONS:The role of PAS in the changing NHS, and the burden such schemes
could entail, is uncertain. Clear guidelines on the impact of healthcare reform are
necessary, alongside additional support to facilitate effective PAS implementation
even after VBP is introduced.
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OBJECTIVES: Pharmaceutical patents have been a useful instrument to promote
innovations in some fields. The signature of the TRIP agreement by the World
Trade Organization (WTO) in 1994 has implied the generalization of a strong patent
system. The objectives of this study is to review some existing alternatives to
patents that may both reduce their negative impact in the accessibility to new
drugs of patients from less developed countries and promote research in neglected
diseases. METHODS: We have reviewed the literature on this field and identified
different alternatives proposed by international institutions as well as by non gov-
ernmental organisations. We describe the options and assess their potential im-
pact on public health. RESULTS: There are several proposals: i) the intensive use of
exceptions and flexibility conditions of Doha=s Declaration, especially, compulsory
licensing, ii) the volunteer licensing through the “patent pool”, iii) GSPOA initiative
that targets the identification and assessment of priorities dealing with R&D re-
ferred to diseases prevalent among the developing countries, iv) the approach
based on prizes, aiming to incentive innovation through competition by separating
the cost of R&D and the price of the drug; v) the Advance Market Commitments to
ex-ante obtain the commitment to fund through donations the new agent once it
has been developed, and vi) the Priority Review Vouchers that provides incentives
to invest in drugs for neglected tropical diseases by offering a transferable voucher
to the pharmaceutical firm that allows a priority review process for the authorisa-
tion of another agent. CONCLUSIONS: Most of the solutions are partial and do not
pursue a radical change in the current patent system. In spite of these proposals,
there are still many diseases with no treatment as the market does not guarantee
a return.
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OBJECTIVES:We aimed to explore the key organizational elements and the degrees
of autonomy that is granted to Iranian corportized hospital (trustees hospitals)
affiliated to Iranian ministry of health after the Iranian health system decentral-
ization reform. METHODS: : All 18 Iranian corportized hospitals (that meet our
criteria) involved to the study. In all, 27 Hospital Top Managers were interviewed
(82% response rate). The semi-structured interview questions were developed us-
ing the Preker and Harding organizational reform Model and in-depth interviews.
The “framework” method was used for the analysis. RESULTS: Nine themes ex-
plain the key organizational elements include: decision right in “strategic”, “hu-
man resources”, “financial” and “physical resources” management, “product” and
“procurement” market exposure, “residual claimant” and “social functions”. Deci-
sion right in “strategic”, “human resources” and “physical resources” management
was very limited. The hospitals were permitted to generate revenue (fee-for- ser-
vices) but weren’t the residual claimant, completely. The hospital was exposed to
product market but limited in procurement market (ceiling payment). Hierarchical
and financial accountability were the main accountability mechanism. Several
insurance programs and governmental budget were used to protect poor people.
CONCLUSIONS:We can see a kind of unbalanced and inconsistent autonomy. More
decision right in “strategic” and “human resources” management, and procure-
ment market should be granted; and also the hospital needs to be the residual
claimant. Government needs a regulatory and accountability mechanism to guar-
antee hospitals performance and balance the revenue generating and social values
objectives.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends, we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase cost effectiveness in abstract of the published
study. RESULTS:During 2005-2010, the number of published studies on cost effec-
tiveness have increased by more than 30%. There is a large variability in CERs for
same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
novel reimbursement schemes for other branded products.CONCLUSIONS:Cancer
drug reimbursement models are setting new benchmark for payers to manage
access and control costs. These models have significant implications for other
expensive branded products.
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ISSUE One approach under consideration for the proposed value based pricing of
pharmaceutical is the UK is to have different willingness to pay thresholds. How-
ever these are problematic to define, lack transparency and not readily understood
by the wider public. OVERVIEW Different willingness to pay thresholds have been
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